Co-Diagnostics, Inc. (CODX) company profile

Co-Diagnostics, Inc. develops, manufactures, and sells molecular diagnostics reagents and testing systems that detect and analyze nucleic acid molecules. The company utilizes its proprietary Co-Primers polymerase chain reaction technology to produce diagnostic tests for infectious diseases, including COVID-19, influenza, tuberculosis, hepatitis, human papillomavirus, malaria, dengue, and Zika. In addition to human medical tests, it provides solutions for identifying genetic traits in plant and animal genomes as well as mosquito surveillance tests. It also develops the portable Co-Dx PCR platform comprising testing instruments, test cups, and mobile software. Its offerings serve clinical laboratories, research partners, and municipal organizations.

The company is headquartered in Salt Lake City, Utah. Its operations and commercial reach include a global distribution network supplying clinical laboratories across more than fifty countries. Furthermore, it operates through a manufacturing and development joint venture in India and maintains regulatory clearances for its diagnostic tests in markets including the United States, the European Community, the United Kingdom, Australia, Mexico, and India.

Summary of the business section of Co-Diagnostics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $6.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 115 full-time and part-time employees at our executive offices and lab facilities in Salt Lake City, Utah.”